An FDA-approved HDAC inhibitor named SAHA reduced the size of heart cells and the thickness of ventricular walls in a new cat model of heart failure (right, compared to control in middle).

Encouraging results have been reported from Phase I clinical trials of suberoylanilide hydroxamic acid (SAHA) ?an inhibitor of histone deacetylase (HDAC). The drug was given orally or ...